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Recent advances in manipulating targeted genes in a tissue-
specific manner have opened the way to the development
of relevant mouse models for the molecular dissection of
the events leading to breast cancer. However, when judging
the appropriateness of any given mouse model, it is impor-
tant to remember that breast cancer comprises a heteroge-
neous group of diseases characterized by different sets of
genetic mutations, histopathological types and metastatic
potentials, often within the same primary tumour mass. It is
unlikely that any single mouse model will be able to mimic
all these aspects of human breast cancer but this does not
invalidate their use in studying specific aspects of the
disease. Mouse models are particularly valuable for defining
the molecular pathways participating in mammary epithe-
lial cell transformation and disease progression, for identify-
ing modifier genes that affect penetrance of the
manipulated gene and for testing various therapeutic and
preventative approaches. The paper by Xu et al [1] in a
recent edition of Nature Genetics describes a new model that
offers promise in several respects.
To put the new model in perspective, we need briefly to
consider the historical background on mouse models of
human cancers. From the 1950s, much effort has been put
into describing and classifying spontaneous, viral- and
carcinogen-induced mammary tumours in rats and mice,
and these models have proven value in toxicology and
drug testing. Mice infected with the mouse mammary
tumour virus (MMTV) have played a large part in our
understanding of insertional mutagenesis and activation of
oncogenes leading to mammary tumourigenesis [2].
However, only a few of the human homologues of these
genes are mutated in human breast cancers although the
signalling pathways through which these genes act have
been implicated. In carcinogen-induced rat mammary
tumours there is a high incidence of ras mutations, which
are very rare in human breast cancers. Thus, although
these models are valuable tools for the dissection of the
complex signalling pathways through which these genes
act, they do not necessarily represent the exact genetic
events that precipitate human breast cancers.
Transgenic technology has recently facilitated the develop-
ment of an entirely new set of genetically engineered
mouse models that can be used to define the transforming
potential of genes implicated in human breast cancer [3,4].
The seminal work of Stewart et al [5] has shown that a c-myc
transgene expressed in the mammary gland under the regu-
lation of the MMTV long-terminal repeat (LTR) induces
mammary tumours. Webster et al [6] have extended this
work, and demonstrate how sophisticated targeted muta-
genesis can be applied to dissecting signalling pathways.
The paper by Xu et al [1] now demonstrates the power of
conditional mutagenesis to specifically delete a gene rele-
vant to human hereditary breast cancer (BRCA1) from the
mouse mammary gland. BRCA1 mutations are known to
account for a significant proportion of familial breast
cancers. BRCA1 contains a region that interacts with
RAD51, a homologue of bacterial RecA, which is involved
in DNA repair, and is believed to be important in main-
taining genetic stability. Homozygous loss of BRCA1 in
human tumours is thought to allow the accumulation of
mutations in other genes, eventually resulting in tumouri-
genesis. However, progress in studying the effects of
BRCA1 deletion or mutation on breast development and
breast cancer has been delayed because of the lack of an
animal model. Mice bearing homozygous null mutations
of  Brca1 die before embryonic day 9, whereas mice
heterozygous for Brca1 deletions do not develophttp://breast-cancer-research.com/vol1no1/02jul99/dispatch/1
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mammary tumours. The paper by Xu et al [1] demon-
strates one way forward that uses a conditional knockout
approach to mutate the intact allele in the mammary
glands of mice bearing heterozygous deletions of Brca1.
This new method uses the Cre-loxP system to induce
mutations in a tissue- and temporal-specific manner [7],
and mimics human disease by producing mice in which
one of the two Brca1 genes has been disabled while the
other carries a mutation that enables it to be disabled in
mammary tissue later in the life of the mouse. Specifically,
it induces mammary tissue specific deletion of Brca1 exon
11 (which encodes the region that interacts with RAD51)
under the control of either an MMTV-Cre or a whey acidic
protein (Wap)-Cre transgene. The MMTV and Wap promot-
ers are maximally activated during pregnancy and lacta-
tion; the Cre-loxP system excises specific DNA sequences
under the control of these tissue-specific promoters. The
model mice thus lose the Brca1 repair function on preg-
nancy and lactation.
The resulting Brca1 conditional knockout appears to
model the molecular mechanism of BRCA1 involvement
in human breast cancer. The mice in which Brca1 function
has been ablated in this way develop mammary-specific
developmental abnormalities and, after a long latency
period, mammary tumours. The molecular pathology of
these tumours resembles that of the carcinomas arising in
human carriers of BRCA1 mutations. A common feature of
the tumours that develop in the mice is aneuploidy and
genetic instability as indicated by chromosomal transloca-
tions. The tumours show rearrangements or translocations
of chromosome 11, and it is stated that rearrangements of
other chromosomes are found. Human BRCA1-associated
tumours also show frequent chromosomal aberrations
[8–10]. It is interesting that two out of three tumours
arising in the conditional Brca1 knock-out mice have
abnormalities in the Trp53 gene. The shortened latency of
tumour development produced by introducing a loss of
function Trp53 allele provides further support for the
important role of TP53 mutations in tumourigenesis in the
BRCA1 mutant background as described in human
tumours [11]. Thus, the Xu mouse is a true breakthrough
as it is the first model in which the mechanisms of genetic
instability and resultant tumourigenesis in the Brca1-defi-
cient mammary gland can be studied. These mice will
undoubtedly be of value in elucidating the early genetic
lesions that promote breast tumourigenesis. Furthermore,
they should be useful for investigating the effects of an
array of suspected agents in breast cancer because of their
increased sensitivity to DNA-damaging insults.
The comparative histopathology is an important element
in validating a mouse model and has implications for
deducing the stem cell of origin, and predicting future
behaviour of the tumour. The differences in the
histopathology of the tumours arising in mice compared to
those in women have been a major limitation of many
mouse models, especially as they suggest a different target
cell population for the initiating event. Comparisons have
been complicated by the lack of an internationally
accepted terminology for both the normal glandular struc-
ture and the tumours that arise in the mammary glands of
rats and mice. In transgenic models, interpretation of
pathology is further complicated by the currently used
promoters, which may direct recombination to cells at dif-
ferent stages of differentiation or to cell lineages different
from those commonly mutated in human cancers. The
Wap promoter is expressed primarily during pregnancy
and lactation throughout the mammary tree and one
advantage is that the lumenal cell population only is the
target. The MMTV-LTR, also used to generate Brca1
conditional knockouts, has the disadvantage of being
active in many tissues. Despite these caveats, however, it
is clear that the tumours arising in the Brca1-deficient
animals have many of the morphological features seen in
human breast cancers. It will now be important to evaluate
the model in terms of invasion of these tumours, lymph
node involvement and the pattern of dissemination, as
mouse models of metastasis to organs other than the lung,
such as the brain and bones, are very much needed. This
could be difficult to ascertain in the Xu model, given the
long latency to tumourigenesis, but will be well worth the
effort. It will also be important to assess the patterns of
expression of molecular markers such as the receptors for
oestrogen and progesterone. The faithfulness of the Xu
model in this respect will determine its value for biochem-
ical analyses and treatment studies. Now that it has been
shown that Brca1-deficient mice do develop mammary
tumours, future models may be prepared using new, more
selective promoters as they are identified.
Counsellors working with women who carry BRCA1 muta-
tions can only give them a statistical probability of the like-
lihood of developing cancer by a given age; this is an
unsatisfactory basis for making high-stake decisions regard-
ing preventative strategies. Differences in penetrance
among different ethnic populations are becoming appar-
ent. These can be attributed either to specific BRCA1
mutations or to allelic variants in modifier loci. Inbred mice
are undoubtedly the most powerful experimental system
for identifying modifier genes and an example of their use-
fulness is the identification of Pla2g2a, encoding a secre-
tory phospholipase, as a major modifier of intestinal
neoplasm formation in adenomatous polyposis coli (Apc)-
deficient mice [12]. However, the conditionally mutant
Brca1 allele was generated using outbred mice, which
limits immediate use for mapping modifiers. The MMTV-
Cre and Wap-Cre transgenic lineages are also on segregating
backgrounds, compounding the complications for mapping
already presented by the cross needed to produce the
recombined allele. This particular model is therefore not
yet ideal for detecting additional predisposing genes.Breast Cancer Research    Vol 1 No 1 Gusterson et al
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Finally, transgenic mice have been used successfully in
the development of gene-based therapies such as the
farnesyl transferase inhibitor approach to treating ras-
mediated tumours. The work in Mark Greene’s labora-
tory, showing that ErbB2-expressing mammary tumours
could be inhibited in vivo by treatment with monoclonal
antibodies to the receptor [13], was an important step in
the development of Herceptin® (Genentech Inc, South
San Francisco, California, USA). Because the Brca1-
deficient mice appear to model the molecular mechanisms
of human BRCA1-associated tumours, they should be
valuable to the development of gene-based preventative
or therapeutic strategies. In particular, they may be useful
for testing therapies that induce apoptosis through Trp53-
independent pathways.
Clearly, the ability to delete Brca1 in a tissue-specific
manner is a breakthrough in the development of animal
models of the molecular mechanisms of BRCA1-associated
breast cancer in humans. This alone will make it a very
useful model for understanding how cells that have lost
Brca1 become transformed, and for testing treatments
aimed at blocking that process. There will be a lot of
excitement in the scientific community as the remaining
elements of this model are evaluated and we would
encourage Xu et al to make the mice available to the com-
munity so that different aspects of its ability to model
human disease are efficiently tested.
References
1. Xu X, Wagner K-U, Larson D, et al: Conditional knockout of BRCA1
in mammary epithelial cells results in blunted ductal morphogen-
esis and tumor formation. Nat Genet 1999, 22:37–43.
2. Callahan R: MMTV-induced mutations in mouse mammary
tumours: Their potential relevance to human breast cancer. Breast
Cancer Res Treatment 1996, 39:33–44.
3. Cardiff RD, Munn RJ: The histopathology of transgenes and knock-
outs in the mammary gland. Advan Oncobiol 1998, 2:177–202.
4. http://www-mp.ucdavis.edu/tgmice/firststop.html
5. Stewart TA, Pattengale PK, Leder P: Spontaneous mammary ade-
nocarcinomas in transgenic mice that carry and express MTV/myc
fusion genes. Cell 1984, 38:627–637.
6. Webster MA, Hutchinson JN, Rauh MJ, et al: Requirement for both
Shc and phosphatidylinositol 3¢ ¢ kinase signalling pathways in
polyomavirus middle T-mediated mammary tumorigenesis. Mol
Cell Biol 1998, 18:2344–2359.
7. Kuhn R, Schwenk F, Aguet M, Rajewsky K: Inducible gene targeting
in mice. Science 1995, 269:1427–1429.
8. Tirkkonen M, Johannsson O, Agnarsson BA, et al: Distinct somatic
genetic changes associated with tumor progression in carriers of
BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57:
1222–1227.
9. Crook T, Brooks LA, Crossland S, et al: Frequent p53 mutations
without a mutator phenotype in BRCA2-associated breast
tumours. Oncogene 1998,  17:1681–1689.
10. Smith PD, Crossland S, Parker G, et al: Novel p53 mutants selected
in BRCA-associated tumours which dissociate transformation
suppression from other wild-type p53 functions. Oncogene 1999,
18:2451–2459.
11. Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of
differences between sporadic breast cancers and cancers involv-
ing BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:
1138–1145.
12. Cormier RT, Hong KH, Halberg RB, et al: Secretory phospholipase
Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet
1997, 17:88–91.
13. Drebin JA, Link VC, Greene MI: Monoclonal antibodies reactive with
distinct domains of the neu oncogene-encoded p185 molecule exert
synergistic anti-tumor effects in vivo. Oncogene 1988, 2:273–277.
Author addresses: Barry Gusterson, Beatrice Howard, Tim Crook
(The Breakthrough Toby Robins Breast Cancer Research Centre,
Institute of Cancer Research, London, UK) and Barbara Tennent (The
Jackson Laboratory, Bar Harbor, Maine, USA)
Correspondence: Barry Gusterson, The Breakthrough Toby Robins
Breast Cancer Research Centre, Institute of Cancer Research,
237 Fulham Road, London SW3 6JB, UK. E-mail: barryg@icr.ac.uk